

23/01/2019

Test report L18/0861MV.1

Evaluation of the effectiveness of Chemisept gel

Test virus: modified vaccinia virus Ankara (MVA)

Method: EN 14476:2013+A1:2015 (dirty conditions)

quantitative suspension test for the evaluation
of virucidal activity of chemical disinfectants and
antiseptics used in human medicine

Sponsor:

Chemi-Pharm AS
Pollu 132
EST – TALLINN 10917

Norderoog 2, DE - 28259 Bremen
Tel.: +49 40-557631-0, Fax: +49 40-557631-11
info@brillhygiene.com, <http://www.brillhygiene.com>



1. Identification of test laboratory

Dr. Brill + Partner GmbH Institute for Hygiene and Microbiology, Norderoog 2, DE - 28259 Bremen

2. Identification of sample

Manufacturer	Chemi-Pharm AS
Name of product	Chemisept gel
Confirmation no.	207507
Product diluent recommended by the manufacturer	-
Batch number	198201118
Application	hand disinfection
Production date	20/11/2018
Expiry date	20/11/2021
Active compound (s) (100 g)	72.5 g ethanol 7.5 g propan-2-ol
Appearance, odour	clear, colorless gel product specific
pH-values	undiluted: 5.08 (20 °C)
Storage conditions	room temperature in the dark (area with restricted access)
Date of arrival in the laboratory	21/11/2018

3. Materials

3.1 Culture medium and reagents

- Eagle's Minimum Essential Medium with Hank's BSS (MEM, Biozym Scientific GmbH, catalogue no. 880144)
- fetal calf serum (Biochrom AG, article no. S 0115)
- 1.4 % formaldehyde solution (dilution of Roti®-Histofix 4 %, Carl Roth GmbH)
- Aqua bidest. (SG ultrapure water system, type Ultra Clear; serial no. 86996-1)
- PBS (Invitrogen, article no. 18912-014)
- BSA (Sigma-Aldrich-Chemie GmbH, article no. CA-2153)

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Anerkannt durch/Recognized by
Zentrale Liste der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukt
www.zlg.de

- sheep erythrocytes (Fiebig Nährstofftechnik).

3.2 Virus and cells

The modified vaccinia virus Ankara (MVA) originated from Dr. Manteufel, Institut für Tierhygiene und Öffentliches Veterinärwesen, DE - 04103 Leipzig. Before inactivation assays, virus had been passaged three times in *BHK 21-cells* (Baby Hamster Kidney).

BHK 21-cells (passage 108) originated from the Friedrich-Löffler-Institut, Bundesforschungsinstitut für Tiergesundheit (formerly Bundesforschungsanstalt für Viruskrankheiten der Tiere, isle of Riems).

The cells were inspected regularly for morphological alterations and for contamination by mycoplasmas. No morphological alterations of cells and no contamination by mycoplasmas could be detected.

3.3 Apparatus, glassware and small items of equipment

- CO₂incubator, Nunc GmbH & Co. KG, model QWJ 350
- Agitator (Vortex Genie Mixer, type G 560E)
- pH measurement 315i (WTW, article no. 2A10-100)
- Centrifuge (Sigma-Aldrich-Chemie GmbH, type 113)
- Microscope (Olympus, type CK 30)
- Centrifuge 5804 R (Eppendorf AG)
- Water bath (JULABO, Julabo U 3)
- Adjustable and fixed-volume pipettes (Eppendorf AG)
- Polyesterol 96-well microtitre plate (Nunc GmbH & Co. KG, Wiesbaden)
- Cell culture flask (Nunc GmbH & Co. KG, Wiesbaden)
- Sealed test tubes (Sarstedt AG & Co., Nümbrecht).

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



ZLG-AP-216.11.02



4. Experimental conditions

Test temperature	20 °C ± 1.0 °C
Concentration of test product	undiluted (80.0 %) and as 50.0 % and 10.0 % (demonstration of non-active range) solutions
Appearance of product dilutions	no precipitation
Contact times	15 and 30 seconds and 30 minutes
Interfering substance	3.0 g/l bovine serum albumin + 3.0 ml/l erythrocytes (dirty conditions, EN 14476)
Procedure to stop action of disinfectant	immediate dilution
Diluent	Aqua bidest.
Stability of product in the mix with virus and interfering substance (80.0 % solution)	minor clouding, medium precipitation
Virus strain	modified vaccinia virus Ankara (MVA) (ATCC VR-1508)
Date of testing	10/12/2018 – 23/01/2019
End of testing	23/01/2019

5. Methods

5.1 Preparation of test virus suspension

For preparation of test virus suspension, *BHK 21-cells* were cultivated with MEM and 10 % or 2 % fetal calf serum.

Cells were infected with a multiplicity of infection of 0.1. After cells showed a cytopathic effect, they were subjected to a freeze/thaw procedure followed by a low speed centrifugation in order to sediment cell debris. After aliquotation, test virus suspension was stored at – 80 °C.

5.2 Preparation of disinfectant (dilutions)

The test product was tested undiluted. Due to the addition of interfering substance and test virus suspension an 80.0 % solution resulted.

Furthermore, the product was evaluated as 50.0 % and 10.0 % solutions (demonstrating of non-active range). These solutions were prepared with Aqua bidest. immediately before the inactivation tests.

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



5.3 Infectivity assay

Infectivity was determined as endpoint titration according to EN 5.5 transferring 0.1 ml of each dilution into eight wells of a microtitre plate to 0.1 ml of freshly trypsinised *BHK 21-cells* ($10\text{-}15 \times 10^3$ cells per well), beginning with the highest dilution. Microtitre plates were incubated at 37°C in a 5 % CO_2 -atmosphere. The cytopathic effect was read by using an inverted microscope after six days. Calculation of the infective dose $\text{TCID}_{50}/\text{ml}$ was calculated with the method of Spearman (2) and Kärber (3) with the following formula:

$$- \log_{10}\text{TCID}_{50} = X_0 - 0.5 + \sum r/n$$

meaning

X_0 = \log_{10} of the lowest dilution with 100 % positive reaction

r = number of pos. determinations of lowest dilution step with 100 % positive and all higher positive dilution steps

n = number of determinations for each dilution step.

5.4 Calculation and verification of virucidal activity

The virucidal activity of the test disinfectant was evaluated by calculating the decrease in titre in comparison with the control titration without disinfectant. The difference is given as reduction factor (RF).

According to the EN 14476, a disinfectant or a disinfectant solution at a particular concentration is having virus-inactivating efficacy if the titre is reduced at least by $4 \log_{10}$ steps within the recommended exposure period. This corresponds to an inactivation of $\geq 99.99\%$.

5.5 Inactivation assay

Determination of virucidal activity has been carried out according to EN 5.5. The test product was examined undiluted (80.0 %) and as 50.0 % and 10.0 % (demonstration of non-active range) solutions in Aqua bidest. at 20°C according to EN 14476. 15 and 30 seconds and 30 minutes were chosen as contact times.

Immediately at the end of a chosen contact time, activity of the disinfectant was stopped by dilution to 10^{-8} .

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019





Titrations of the virus control were performed at the beginning of the test and after the longest exposure time (EN 5.5.7). One part by volume of test virus suspension was mixed with one part interfering substance and eight parts by volume of WSH or Aqua bidest. (RTU products).

Furthermore, a cell control (only addition of medium) was incorporated.

Inactivation tests were carried out in sealed test tubes in a water bath at $20\text{ }^{\circ}\text{C} \pm 1.0\text{ }^{\circ}\text{C}$. Aliquots were retained after appropriate exposure times and residual infectivity was determined.

5.6 Determination of cytotoxicity

Determination of cytotoxicity was performed according to EN 5.5.4.1.

5.7 Cell sensitivity to virus

For the control of cell sensitivity to virus two parts by volume of water were mixed with eight parts by volume of the lowest apparently non-cytotoxic dilution of the product. These mixtures or PBS as control were added to a volume of double concentrated cell suspension. After 1 h at $37\text{ }^{\circ}\text{C}$ the cells were centrifuged and re-suspended in cell culture medium (EN 5.5.4.2b).

Finally, a comparative titration of the test virus suspension was performed on the pre-treated (disinfectant) and non-pre-treated (PBS) cells as described above.

5.8 Control of efficacy for suppression of disinfectant's activity

Furthermore, a control of efficiency for suppression of disinfectant's activity was included (EN 5.5.5).

5.9 Reference virus inactivation test

As reference for test validation a 0.7 % formaldehyde solution according to EN 5.5.6 was included. 5, 15, 30 and 60 minutes were chosen as contact times. In addition, cytotoxicity of formaldehyde test solution was determined according to EN 5.5.6.2 with dilutions up to 10^{-5} .

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



ZLG-AP-216.11.02



6. Verification of the methodology

The following criteria as mentioned in EN 5.7 were fulfilled:

- a) The titre of the test virus suspension allowed the determination of a $\geq 4 \log_{10}$ reduction (maximal virus reduction $\geq 4.50 \pm 0.27$)
- b) The test product (80.0 %) showed cytotoxicity in the 1:10 dilutions thus allowing the detection of a $4 \log_{10}$ reduction of virus titre.
- c) The comparative titration on pre-treated (disinfectant) and non-pre-treated (PBS) BHK 21-cells showed no significant difference ($< 1 \log_{10}$; EN 5.7) of virus titre: 6.75 ± 0.33 (PBS) versus 6.75 ± 0.44 (1:100 dilutions of disinfectant as 80.0 % solution) \log_{10} TCID₅₀/ml.
- d) The control of efficacy for suppression of disinfectant's activity (80.0 %) showed a decrease of 0.88 (6.13 ± 0.37 versus $7.00 \pm 0.38 \log_{10}$ TCID₅₀/ml) and failed the requirement of the EN ($\leq 0.5 \log_{10}$; EN 5.5.5.1). This was due to the fact that even the 10.0 % solution showed a slight reduction of virus titre (RF = 0.63 ± 0.45 after 30 minutes). In these experiments at the end of the defined exposure time the test mixture was immediately diluted and the dilutions transferred to the cell culture. Therefore, despite the insufficient control of efficacy for suppression of disinfectant's activity the assay is valid.
- e) One concentration demonstrated a $4 \log_{10}$ reduction and (at least) one concentration demonstrated a \log_{10} reduction of less than 4.

Since all criteria according EN 5.7 were fulfilled, examination with MVA according to EN 14476 is valid.

7. Results

Results of examination are shown in tables 1 to 8. Tables 1 to 7 demonstrate the raw data, whereas table 8 (a+b) gives a summary of results.

The undiluted test product (80.0 %) was able to inactivate MVA after 15 seconds of exposure time under dirty conditions (tables 1 and 2). The reduction factors were $\geq 4.00 \pm 0.33$ and $\geq 4.50 \pm 0.27$. The mean value was $\geq 4.25 \pm 0.21$. This corresponded to an inactivation of $\geq 99.99\%$.

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Anerkannt durch/Recognized by
Zentrale Laboratorium für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukt
www.zlg.de

ZLG-AP-216.11.02



The test product as 50.0 % solution was also able to inactivate MVA after 15 seconds of exposure time under dirty conditions (table 3). The reduction factor was $\geq 4.13 \pm 0.56$. This corresponded to an inactivation of $\geq 99.99\%$.

Testing the product as 10.0 % solution, no activity was found within 30 minutes (table 4).

8. Conclusion

The hand disinfectant Chemisept gel tested undiluted demonstrated activity against MVA after an exposure time of 15 seconds under dirty conditions.

Therefore, the hand disinfectant Chemisept gel can be declared as active against MVA as follows:

undiluted 15 seconds dirty conditions

Bremen, 23/01/2019

- Dr. Britta Becker -
Head of Laboratory

- Dr. Dajana Paulmann -
Scientific Project Manager



*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



ZLG-AP-216.11.02

9. Quality control

The Quality Assurance of the results was maintained by performing the determination of the virus-inactivating properties of the disinfectant in accordance with Good Laboratory Practice regulations:

- 1) Chemicals Act of Germany, Appendix 1, dating of 01.08 1994 (BGBI. I, 1994, page 1703). Appendix revised at 14. 05. 1997 (BGBI. I, 1997, page 1060).
- 2) OECD Principles of Good Laboratory Practice (revised 1997); OECD Environmental Health and Safety Publications; Series on Principles of Good Laboratory Practice and Compliance Monitoring – Number 1. Environment Directorate, Organization for Economic Co-operation and Development, Paris 1998.

The plausibility of the results was additionally confirmed by controls incorporated in the inactivation assays.

10. Records to be maintained

All testing data, protocol, protocol modifications, the final report, and correspondence between Dr. Brill + Partner GmbH and the sponsor will be stored in the archives at Dr. Brill + Partner GmbH.

The use of the Dr. Brill + Partner GmbH name, logo or any other representation of Dr. Brill + Partner GmbH, other than distribution of this report in its entirety, without the written approval of Dr. Brill + Partner GmbH is prohibited. In addition, Dr. Brill + Partner GmbH may not be referred to in any form of promotional materials, press releases, advertising or similar materials (whether by print, broadcast, communication or electronic means) without the express permission of Dr. Brill + Partner GmbH.

The test results in this test report relate only to the items examined.

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



DAKKS
Deutsche
Akkreditierungsstelle
D-PL-13412-01-01
D-PL-13417-01-02

Anerkannt durch/Recognized by
Zentralstelle der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukt
ZLG ZLG-AP-216.11.02
www.zlg.de



11. Literature

1. EN 14476:2013+A1:2015: Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity of chemicals disinfectants and antiseptics in human medicine test - Test method and requirements (phase 2, step 1)
2. Spearman, C.: The method of 'right or wrong cases' (constant stimuli) without Gauss's formulae.
Brit J Psychol; 2 1908, 227-242
3. Kärber, G.: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche.
Arch Exp Path Pharmak; 162, 1931, 480-487

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Deutsche
Akkreditierungstelle
D PL-13412 01-01
D PL-13412 01-02



Anerkannt durch/Recognized by
Zentrale Liste der Länder
für Gesundheitsaufsicht
bei Arzneimitteln und
Medizinprodukt
www.zlg.de
ZLG-AP-216.11.02

Appendix:

Legend to the Tables

Table 1: Raw data for Chemisept gel (80.0 %) tested against MVA (1st assay)

Table 2: Raw data for Chemisept gel (80.0 %) tested against MVA (2nd assay)

Table 3: Raw data for Chemisept gel (50.0 %) tested against MVA

Table 4: Raw data for Chemisept gel (10.0 %) tested against MVA

Table 5: Raw data for formaldehyde solution (0.7 %) tested against MVA

Table 6: Raw data for control of efficacy for suppression of disinfectant's activity (80.0 %)

Table 7: Raw data (MVA) for cell sensitivity (80.0 %)

Table 8 (a+b): Summary of results with Chemisept gel and MVA

Legend to the Figures

Figure 1: Virus-inactivating properties of Chemisept gel (80.0 %)

Figure 2: Virus-inactivating properties of formaldehyde (0.7 %)

*Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



ZLG-AP-216.11.02



Table 1: Raw data for Chemisept gel (80.0 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5829) (1st assay)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (\log_{10})					
				1	2	3	4	5	6
test product 80.0 %	dirty conditions	0.25	tttt	0000	0000	0000	0000	0000	0000
			tttt	0000	0000	0000	0000	0000	0000
			tttt	0000	0000	0000	0000	0000	0000
		0.5	tttt	0000	0000	0000	0000	0000	0000
			tttt	0000	0000	0000	0000	0000	0000
			tttt	0000	0000	0000	0000	0000	0000
test product cytotoxicity	80.0 %	dirty conditions	n.a.	60	n.d.	n.d.	n.d.	n.d.	n.d.
virus control	n.a.	dirty conditions	0	4444	4444	4444	4444	2322	0000
				4444	4444	4444	4444	0433	0002
				4444	4444	4444	4444	3203	0003
				4444	4444	4444	4444	2033	0020

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28759 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019

Table 2: Raw data for Chemisept gel (80.0 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5863) (2nd assay)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (\log_{10})					
				1	2	3	4	5	6
test product 80.0 %	dirty conditions		0.25	tttt tttt	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
			0.5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			60	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
test product cytotoxicity 80.0 %	dirty conditions	n.a.	tttt tttt	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
virus control	n.a.	dirty conditions	0	4444 4444	4444 4444	4444 4444	4444 4444	2333 4444	0030 0000
			60	4444 4444	4444 4444	4444 4444	4444 4444	3334 2344	0000 0000
								0000 0000	0000 0000

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Table 3: Raw data for Chemisept gel (50.0 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5863)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (\log_{10})					
				1	2	3	4	5	6
test product 50.0 %	dirty conditions		0.25	n.d.	0000 0204	0000 0200	0000 0000	0000 0000	0000 0000
			0.5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			60	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
test product cytotoxicity 50.0 %	dirty conditions	n.a.	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0030 0000	0000 0000
virus control	n.a.	dirty conditions	0	4444 4444	4444 4444	4444 4444	4444 4444	4444 4444	3343 2344
			60	4444 4444	4444 4444	4444 4444	4444 4444	4444 4444	0000 0000
									0000 0000

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019





Table 4: Raw data for Chemisept gel (10.0 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5863)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (\log_{10})					
				1	2	3	4	5	6
test product 10.0 %	dirty conditions		0.25	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			0.5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
test product 10.0 %	dirty conditions		30	n.d.	4444	4444	4444	3430	0000
					4444	4444	4444	2233	0000
virus control	n.a.	dirty conditions	0	0000	0000	0000	0000	0000	0000
			60	4444	4444	4444	4444	2333	0030
				4444	4444	4444	4444	4444	0000
					3334	3334	3343	0000	0000
					2344	2344	0000	0000	0000
								0000	0000

n.a. = not applicable

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

Table 5: Raw data for formaldehyde solution (0.7 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5863)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (\log_{10})					
				1	2	3	4	5	6
formaldehyde 0.7 % (m/V)	PBS	n.a.	5	tttt	tttt	0202	0000	0000	0000
			15	tttt	tttt	0004	0000	0000	0000
			30	tttt	tttt	0000	0000	0000	0000
			60	tttt	tttt	0000	0000	0000	0000
formaldehyde cytotoxicity 0.7 % (m/V)	PBS	n.a.	tttt	tttt	tttt	0000	0000	0000	0000
virus control	n.a.	PBS	0	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			60	4444	4444	4444	4444	3230	0030
				4444	4444	4243	4243	0000	0000
								0000	0000

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019





Table 6: Raw data for control of efficacy for suppression of disinfectant's activity (80.0 %) (#5863)

Product	Interfering substance	dilutions (\log_{10})								
		1	2	3	4	5	6	7	8	9
test product	dirty conditions	tttt	4444	4444	4444	0434	0000	0000	0000	n.d.
corresponding virus control	dirty conditions	4444	4444	4444	4444	3334	3343	0000	0000	0000

n.a. = not applicable

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

n.d. = not done

* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28759 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Table 7: Raw data (MVA) for cell sensitivity (80.0 % solution) (#5863)

Product	Dilution	Dilutions (\log_{10})						
		1	2	3	4	5	6	7
PBS	-	4444	4444	4444	4444	4433	0002	0000
		4444	4444	4444	4444	4443	0400	0000
test product	1:100	4444	4444	4444	4444	4333	0024	0000
		4444	4444	4444	4444	0324	2000	0000
								n.d.

n.a. = not applicable

0 = no virus present; t = cytotoxic

1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

n.d. = not done

* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019

Table 8a: Summary of results with Chemisept gel and MVA

Product*	Concentration	Interfering substance	Level of cytotoxicity	\log_{10} TCID _{50/ml} aftermin				$> 4 \log_{10}$ reduction after ...min
				0.25	0.5	5	30	
test product (1)	80.0 %	dirty conditions	2.50	$\leq 2.50 \pm 0.00$	n.d.	n.d.	n.d.	0.25 (RF $\geq 4.00 \pm 0.33$)
test product (2)	80.0 %	dirty conditions	2.50	$\leq 2.50 \pm 0.00$	n.d.	n.d.	n.d.	0.25 (RF $\geq 4.50 \pm 0.27$)
test product (2)	50.0 %	dirty conditions	1.50	$\leq 2.88 \pm 0.41$	n.d.	n.d.	n.d.	0.25 (RF $\geq 4.13 \pm 0.56$)
test product (2)	10.0 %	dirty conditions	1.50	n.d.	n.d.	6.38 ± 0.25	n.d.	> 30 (RF = 0.63 ± 0.45)

* The number in brackets gives the number of the corresponding virus control, see table 8b

n.a. = not applicable n.d. = not done

* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019

Table 8b: Summary of results with Chemisept gel and MVA

Product	Concentration	Interfering substance	Level of cytotoxicity	\log_{10} TCID ₅₀ /ml aftermin				> 4 \log_{10} reduction after ... min
				0	5	15	30	
formaldehyde	0.7 % (w/v)	PBS	4.50	n.d.	$\leq 4.88 \pm 0.37$	$\leq 4.50 \pm 0.00$	$\leq 4.50 \pm 0.00$	$\leq 4.50 \pm 0.00$
virus control	n.a.	PBS	n.a.	n.d.	n.d.	n.d.	n.d.	≥ 15 (RF $\geq 2.00 \pm 0.25$)
virus control (1)	n.a.	dirty conditions	n.a.	6.50 ± 0.35	n.d.	n.d.	n.d.	n.a.
virus control (2) (+ suppression)	n.a.	dirty conditions	n.a.	6.63 ± 0.25	n.d.	n.d.	n.d.	6.50 ± 0.46
suppression control	80.0 %	dirty conditions	2.50	n.d.	n.d.	n.d.	n.d.	n.a.
sens. PBS	n.a.	n.a.	n.a.	n.d.	n.d.	n.d.	n.d.	6.75 ± 0.33
sens. product	80.0 % → 1:100	n.a.	n.a.	n.d.	n.d.	n.d.	n.d.	6.75 ± 0.44

n.a. = not applicable n.d. = not done sens. = sensitivity


* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49-40-557631-0, Telefax +49-40-557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Akkreditiert durch/Recognized by
Zertifizierte Gesundheitsschutz- und Medizinprodukte
bei Ärzten/Arzneimitteln und
Medizinprodukten

ZLG-AP-216.11.02

Figure 1: Virus-inactivating properties of Chemisept gel (80.0 %)



* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Anerkennung durch/Recognized by
Zertifizierte der Länder:
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukt
ZLG-AP-216.11.02



DIN EN ISO 9001


Deutsche

Akkreditierungsstelle

DR-PR-1342-57-02

ZLG-AP-216.11.02

Figure 2: Virus-inactivating properties of formaldehyde (0.7 %)



* Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2019



Ankertenn durch Erkennung by
Zertifizierung der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukten
ZLG-AP-216.11.02

Ankertenn durch Erkennung by
Zertifizierung der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukten
ZLG-AP-216.11.02

